International Journal of Cancer

Papers
(The H4-Index of International Journal of Cancer is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Issue Information785
Issue Information277
229
Issue Information137
Latent class analysis‐derived classification improves the cancer‐specific death stratification of lymphomas: A large retrospective cohort study124
Issue Information117
Assessment of long‐term survival in childhood cancer patients using cancer registry data from eastern China: Period analysis outperforms traditional analysis96
A comprehensive investigation of histotype‐specific microRNA and their variants in Stage I epithelial ovarian cancers80
Issue Information74
Comments on “Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer”71
71
Improving colon cancer screening in Poland. In search of the Holy Grail66
Pre‐diagnostic circulating resistin concentrations and mortality among individuals with colorectal cancer: Results from the European Prospective Investigation into Cancer and Nutrition study66
Pan‐cancer analysis reveals molecular signatures for predicting matrix stiffness in solid tumors62
Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry‐based study62
Cervical cancer screening: Sharing best practices and addressing common challenges in cervical cancer screening programs61
Erratum59
Prospective evaluation of 92 protein biomarkers for early detection of endometrial cancer57
Education level and risk of breast cancer by tumor subtype in the EPIC cohort57
Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (W56
Delivered relative dose intensity in adolescent and young adult germ cell tumours in England: Assessment of data quality and consistency from clinical trials compared to national cancer registration d56
Prenatal diethylstilbestrol exposure and risk of benign breast disease: The National Cancer Institute Diethylstilbestrol Follow‐up Study56
52
Ovarian cancer survival in sub‐Saharan Africa by human development index and histological subtypes: A population‐based registry study51
Association of aflatoxin with gallbladder cancer in a case‐control study nested within a Chinese cohort50
Physical activity and mortality in melanoma patients within the Norwegian Women and Cancer study (NOWAC)48
Issue Information47
Antiviral prophylaxis for hepatitis B virus reactivation in T‐cell lymphoma patients with resolved hepatitis B virus infection47
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials46
Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study44
DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target44
Timing of surgery and 1‐year postoperative outcomes in patients with breast cancer and preoperative COVID‐19 history: A matched, longitudinal, ambidirectional cohort study44
Maternal illnesses during pregnancy and the risk of childhood cancer: A medical‐record based analysis (UKCCS)43
Celecoxib promotes the efficacy of STING‐targeted therapy by increasing antitumor CD8+ T‐cell functions via modulating glucose metabolism of CD11b+42
Longitudinal changes in health‐related quality of life after a breast cancer diagnosis in sub‐Saharan Africa: Evidence from the prospective ABC ‐ 42
The cervico‐vaginal DNA methylation WID ‐ qEC t41
Development and psychometric properties of a general cancer stigma scale40
Dipeptidyl peptidase‐4 in the tumor microenvironment of the digestive system: Molecular mechanisms and therapeutic targets40
Urokinase Plasminogen Activator Receptor‐Associated Protein ( uPARAP ) as a Potential Next Generation Molecular Target for Treatment of Gastrointesti39
0.14753413200378